Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial-Reference-Cited by-同舟云学术

Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial

Published:2018-04 Issue:2 Volume:16 Page:e315-e322
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Wong Yu-Ning,Manola Judith,Hudes Gary R.,Roth Bruce J.,Moul Judd W.,Barsevick Andrea M.,Scher Richard M.,Volk Michael J.,Vaughn David J.,Williams Stephen D.,Fisch Michael J.,Cella David,Carducci Michael A.,Wilding George

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference22 articles.

1. Abiraterone and increased survival in metastatic prostate cancer;Parker;N Engl J Med,2011

2. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel.

3. Enzalutamide in metastatic prostate cancer before chemotherapy;Beer;N Engl J Med,2014

4. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N Engl J Med,2013

5. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic marker VPS72 could promote the malignant progression of prostate cancer;BMC Cancer;2024-06-10

2. Programmed cell death, redox imbalance, and cancer therapeutics;Apoptosis;2021-07-08